A NOVEL ANTICANCER STRATEGY

Information

  • Research Project
  • 6141750
  • ApplicationId
    6141750
  • Core Project Number
    R43CA083601
  • Full Project Number
    1R43CA083601-01A1
  • Serial Number
    83601
  • FOA Number
  • Sub Project Id
  • Project Start Date
    3/1/2000 - 25 years ago
  • Project End Date
    9/1/2000 - 24 years ago
  • Program Officer Name
    COUCH, JENNIFER A
  • Budget Start Date
    3/1/2000 - 25 years ago
  • Budget End Date
    9/1/2000 - 24 years ago
  • Fiscal Year
    2000
  • Support Year
    1
  • Suffix
    A1
  • Award Notice Date
    2/23/2000 - 25 years ago

A NOVEL ANTICANCER STRATEGY

We propose to develop a platform technology to identify distinguishing features of different forms of cancer based upon their unique expression pattern of RNA transcript forms (Phase I). We further envision the use of these features to detect and destroy the cells that contain them (Phase II). In Phase I, we propose to develop tools to mine the Cancer Genome Anatomy Project (CGAP) database to identify distinguishing molecular features of early cancer cells based upon the unique cancer-specific messenger RNA transcript forms. We will generate EST clusters and subclusters for mRNA transcript forms from various normal and cancer- associated cells and index them to relevant biological data. We will develop query tools to examine the data in a straightforward and meaningful fashion and test hypotheses about gene expression in cancer vs. normal cells. We plan to make the tools available to the scientific community at large. Using the tools ourselves, we 'will identify at least 5 RNA structures unique to (or enriched in) various forms of cancer. We will confirm the predictions experimentally using standard chemical and enzymatic probes. If successful in Phase I, we envision a chemical strategy to exploit these structures for the diagnosis and treatment of cancer in a Phase II proposal. PROPOSED COMMERCIAL APPLICATIONS: Diagnostic and therapeutic products for cancer

IC Name
NATIONAL CANCER INSTITUTE
  • Activity
    R43
  • Administering IC
    CA
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    100000
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    394
  • Ed Inst. Type
  • Funding ICs
    NCI:100000\
  • Funding Mechanism
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    ISIS PHARMACEUTICALS, INC.
  • Organization Department
  • Organization DUNS
  • Organization City
    CARLSBAD
  • Organization State
    CA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    920087327
  • Organization District
    UNITED STATES